Nkarta Q1 2024 Earnings Report
Key Takeaways
Nkarta reported a cash balance of $450.0 million as of March 31, 2024, bolstered by a recent $240.1 million offering, which is expected to fund operations into late 2027. The company's net loss for the quarter was $29.5 million, or $0.58 per share.
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024
Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments
Strong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027
Nkarta expects to announce preliminary data from the NKX019 compressed dosing cohort in mid-2024.
Nkarta
Nkarta
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into late 2027.